- Cat. No.
- A12260
PSB-12379
PSB-12379 is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human).
Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
CD73 inhibitors block ecto-5'-nucleotidase (CD73), the enzyme that forms extracellular adenosine. CD73 is a cell-surface protein held in the membrane by a glycolipid anchor. Together with ectonucleoside triphosphate diphosphohydrolase 1 (CD39), which breaks down ATP, it produces adenosine that suppresses T-cell responses, as shown for regulatory T cells. CD73 inhibitors are therefore used to study the adenosine pathway in tumor immunity and inflammation. Listed compounds include the nucleotide analogs AB-680 and MethADP, the inhibitors PSB-12379 and LY-3475070, and PD-L1/CD-73-IN-1, which also targets programmed death-ligand 1 (PD-L1).
PSB-12379 is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human).
AB-680 is highly potent, reversible and selective small molecule inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.
CD73-IN-1 is an inhibitor of CD73 which can be used in the treatment of cancer extracted from patent WO 2017153952 A1, example 80.
Synonyms: Adenosine 5'-(α,β-methylene)diphosphate
MethADP is a specific CD73 inhibitor.
Synonyms: Adenosine
MethADP (sodium salt) is a specific CD73 inhibitor.
LY-3475070 is a potent and selective CD73 Inhibitor with IC50 of 28 nM.
BK50164 is a selective inhibitor of CD73, exhibiting an IC50 of 13.089 μM. It demonstrates a binding affinity to CD99 with a KD of 1.5 μM. This compound exhibits antiproliferative effects and is capable of inducing apoptosis, as well as causing cell cycle arrest in the Sub-G1 phase. BK50164 is valuable in studies focused on tumor immunology and metabolic regulation.
Out of stock
All 3 sizes
PD-L1/CD-73-IN-1 is a potent inhibitor of PD-L1 and CD73, exhibiting IC50 values of 6 nM and 0.773 μM, respectively. This compound demonstrates significant biological activity by inhibiting tumor cell growth both in vitro and in vivo. It is an essential tool for research applications focused on immune modulation and cancer therapy.
Out of stock
All 3 sizes
CD73-IN-5 is a potent and selective small molecule inhibitor of CD73, exhibiting an IC50 value of 19 nM. This compound effectively interferes with the enzymatic activity of CD73, which plays a critical role in the production of adenosine in the tumor microenvironment. CD73-IN-5 is utilized in research applications exploring immunomodulation, cancer therapy, and the therapeutic potential of targeting adenosine signaling pathways.
CD73-IN-4 is a selective inhibitor of CD73, functioning through the blockade of adenosine production. With an IC50 of 2.6 nM against human CD73, it demonstrates significant potency in modulating immunosuppressive signals in the tumor microenvironment. This compound is valuable for investigating cancer immunology and exploring therapeutic strategies aimed at enhancing anti-tumor immune responses.
OP-5244 is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. By blocking adenosine production, OP-5244 effectively reverses immunosuppression, making it a valuable tool in cancer research. Its application can aid in the exploration of therapeutic strategies aimed at enhancing anti-tumor immunity.
8-BuS-AMP is an inhibitor of NTPDase1, CD73, and CD39, demonstrating an IC50 of 35 μM and a Ki of 0.292 μM for human NTPDase1, alongside Ki values of 1.19 μM for CD73 and 0.847 μM for CD39. This compound interacts with the substrate-binding sites of NTPDase1 and CD73, effectively preventing the conversion of ATP and AMP to adenosine, which promotes the activation and proliferation of human peripheral T lymphocytes. 8-BuS-AMP exhibits robust enzymatic hydrolysis resistance and metabolic stability, and it has no activity against P2Y1 and P2Y12 receptors. This reagent is suitable for investigations into purinergic signaling pathways and cancer research.
ORIC-533 is a selective, orally active inhibitor of CD73 that operates through an AMP-competitive mechanism, demonstrating potent inhibition of adenosine production with a sub-nanomolar affinity (Ka 0.03 nM). This compound has shown significant promise in the context of multiple myeloma, as it enhances the cytotoxic activity of the immune system against tumor cells by reversing immunosuppression, inducing immunogenic cell death, and activating various immune cells including dendritic cells, T cells, and NK cells, while exhibiting minimal toxicity to normal cells. Furthermore, combined administration of ORIC-533 with daratumumab effectively increases intratumoral CD8+ T cell infiltration and substantially inhibits tumor growth in preclinical models.
Out of stock
All 3 sizes
CD73-IN-11 is a potent inhibitor of CD73, an enzyme responsible for converting extracellular 5'-AMP into adenosine. By inhibiting CD73, this compound disrupts adenosine production, which is known to induce immunosuppressive effects and can promote tumor proliferation and metastasis. CD73-IN-11 is an essential tool for studying tumor-related diseases and investigating the role of adenosine in cancer biology.
CD73-IN-2 is a potent inhibitor of CD73, demonstrating an IC50 value of 0.09 nM. This compound effectively interferes with the enzymatic activity of CD73, which plays a critical role in the regulation of extracellular adenosine levels. CD73-IN-2 is valuable for research applications focused on immuno-oncology, inflammation, and metabolic diseases.
Out of stock
All 3 sizes
CD73-IN-19 is a potent CD73 inhibitor, exhibiting a 44% inhibition of CD73 enzymatic activity at 100 μM. It effectively counteracts TCR-induced blockade of T cell proliferation at concentrations of 10 μM and 100 μM, highlighting its role in modulating immune responses. Additionally, CD73-IN-19 has been shown to inhibit hA2A receptor activity in HEK-293 cells, with a Ki value of 3.31 μM. This compound demonstrates potential value in studies related to immune disorders and therapeutic interventions.
Out of stock
All 3 sizes
CD73-IN-10 is a potent inhibitor of CD73, an enzyme that catalyzes the conversion of extracellular 5'-AMP to adenosine. By inhibiting CD73, this compound can reduce the immunosuppressive effects of adenosine, which play a role in tumor proliferation and metastasis. CD73-IN-10 is valuable for research applications focused on tumor biology and the study of tumor-related diseases.
CD73-IN-13 is a potent inhibitor of CD73, an enzyme implicated in tumor growth, angiogenesis, and metastasis. This compound serves as a valuable tool in the investigation of tumor-related diseases, offering insights into the biochemical pathways associated with cancer progression. Researchers can utilize CD73-IN-13 to explore the therapeutic potential of targeting CD73 in various malignancies.
Out of stock
All 3 sizes
CD73-IN-8 is a potent inhibitor of CD73, an enzyme responsible for converting extracellular 5'-AMP to adenosine. Elevated levels of adenosine are associated with immunosuppression and enhanced tumor growth and metastasis. CD73-IN-8 is valuable for investigating tumor-related diseases and exploring therapeutic strategies aimed at modulating the adenosine pathway in cancer research.
CD73-IN-14 is a potent and selective inhibitor of CD73, exhibiting an IC50 of 0.17 nM. This compound enhances the recruitment of tumor-infiltrating CD8+ T cells and demonstrates significant anti-tumor activity. Additionally, CD73-IN-14 features an alkyne group that enables its use in click chemistry applications, facilitating copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing partners. This reagent is valuable for studies in immuno-oncology and chemical biology, allowing for the exploration of immune modulation and therapeutic strategies.
Out of stock
All 3 sizes
ZM522 is a potent CD73 inhibitor with an IC50 value of 0.56 μM. This compound enhances immune activity by elevating interferon-γ (INF-γ) levels and modulating T cell activation. ZM522 is suitable for research applications in immunology and cancer therapy, offering potential insights into immune response mechanisms and therapeutic strategies.
Synonyms: Adenosine 5'-(α,β-methylene)diphosphate trisodium
MethADP trisodium is a potent inhibitor of CD73, targeting the enzymatic conversion of ATP to adenosine. This compound plays a crucial role in studies investigating the ATP-adenosine signaling pathway and its implications in cancer, immunology, and inflammatory diseases. MethADP trisodium is instrumental for researchers exploring the modulation of adenosine levels and the effects on immune cell function.
Out of stock
All 3 sizes
MRS4620 is a potent inhibitor of CD73, exhibiting an inhibitory constant (Ki) of 0.436 nM. This compound is primarily utilized in cancer immunology research, where it can help elucidate the role of CD73 in immune regulation and tumor microenvironment modulation. MRS4620 is valuable for studies aimed at enhancing anti-tumor immunity and understanding the mechanisms of immune evasion in cancer.
Out of stock
All 3 sizes
CD73-IN-9 is a potent inhibitor of CD73, an enzyme that catalyzes the conversion of extracellular 5'-AMP to adenosine. Elevated adenosine levels are associated with immunosuppressive effects and can promote tumor proliferation and metastasis. This compound is valuable for investigating tumor-related diseases and understanding the role of CD73 in cancer biology.
ST80 is an inhibitor of the OTUD4/CD73 interaction. It effectively decreases the protein level of CD73 and enhances its turnover, which reduces the immune evasion capabilities of tumor cells. This results in significant antitumor efficacy, particularly in the context of immunosuppressive triple-negative breast cancer (TNBC), making ST80 valuable for research in cancer immunotherapy.
Out of stock
All 3 sizes